Free Trial
NASDAQ:PRTG

Portage Biotech (PRTG) Stock Price, News & Analysis

Portage Biotech logo
$8.26 -0.99 (-10.70%)
Closing price 04:00 PM Eastern
Extended Trading
$8.19 -0.07 (-0.85%)
As of 06:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Portage Biotech Stock (NASDAQ:PRTG)

Key Stats

Today's Range
$7.96
$9.58
50-Day Range
$4.00
$9.60
52-Week Range
$2.10
$23.01
Volume
265,993 shs
Average Volume
771,227 shs
Market Capitalization
$8.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.

Remove Ads

Portage Biotech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
19th Percentile Overall Score

PRTG MarketRank™: 

Portage Biotech scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Portage Biotech.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Portage Biotech is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Portage Biotech is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Portage Biotech has a P/B Ratio of 2.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Portage Biotech's valuation and earnings.
  • Percentage of Shares Shorted

    8.44% of the float of Portage Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Portage Biotech has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Portage Biotech has recently decreased by 20.69%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Portage Biotech does not currently pay a dividend.

  • Dividend Growth

    Portage Biotech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.44% of the float of Portage Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Portage Biotech has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Portage Biotech has recently decreased by 20.69%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Portage Biotech has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Portage Biotech this week, compared to 0 articles on an average week.
  • Search Interest

    9 people have searched for PRTG on MarketBeat in the last 30 days.
  • MarketBeat Follows

    2 people have added Portage Biotech to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Portage Biotech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    42.07% of the stock of Portage Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 13.36% of the stock of Portage Biotech is held by institutions.

  • Read more about Portage Biotech's insider trading history.
Receive PRTG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Portage Biotech and its competitors with MarketBeat's FREE daily newsletter.

PRTG Stock News Headlines

Portage Biotech Inc. Common Stock (PRTG) Pre-Market
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Portage Biotech presents preclinical data for PORT-7
See More Headlines

PRTG Stock Analysis - Frequently Asked Questions

Portage Biotech's stock was trading at $5.17 at the beginning of the year. Since then, PRTG shares have increased by 59.8% and is now trading at $8.26.
View the best growth stocks for 2025 here
.

Portage Biotech Inc. (NASDAQ:PRTG) announced its quarterly earnings data on Tuesday, November, 26th. The company reported ($1.26) earnings per share (EPS) for the quarter.

Portage Biotech shares reverse split on the morning of Thursday, August 15th 2024. The 1-20 reverse split was announced on Tuesday, August 13th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of PRTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Portage Biotech investors own include Meta Platforms (META), Alimera Sciences (ALIM), Angion Biomedica (ANGN), AirNet Technology (ANTE), Broadcom (AVGO), Barnwell Industries (BRN) and Catalyst Biosciences (CBIO).

Company Calendar

Last Earnings
11/26/2024
Today
4/01/2025
Next Earnings (Estimated)
4/04/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PRTG
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-75,340,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
$15.95 per share
Price / Cash Flow
0.58
Book Value
$3.74 per share
Price / Book
2.47

Miscellaneous

Free Float
608,000
Market Cap
$9.70 million
Optionable
Optionable
Beta
1.29
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:PRTG) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners